IDH2 and chronic myelogenous leukemia, BCR-ABL1 positive: Firstly, the hypothesis of new mutations not sensitive to enasidenib, as observed with tyrosine kinase inhibitors in chronic myeloid leukemia (CML), is not retained by the authors because no new IDH2 mutations were identified.